FDA Approves LENALIDOMIDE — BIOCON PHARMA INC.,

# FDA Approves BIOCON PHARMA's Generic Lenalidomide, Expanding Access to Key Multiple Myeloma Treatment BIOCON PHARMA INC. has received FDA approval for its generic lenalidomide oral formulation (ANDA215759), marking a significant entry into the competitive immunomodulatory drug market and expected to increase patient access while creating pricing pressure on the branded Revlimid formulation. The approval is anticipated to capture meaningful market share in the multiple myeloma and myelodysplastic syndromes segments, where lenalidomide remains a